We only have this paper's title and publication details.
Read it at the sourcePhase I trial evaluates safety and pharmacokinetics of intravenous sotrovimab 3000 mg, suggesting tolerability in patients.
ClinicalTrials.gov NCT05280717; date of registration 4 March, 2022.
No takes yet. Share an insight, caveat, or question.
Bhangu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: